Travere Therapeutics, Inc. (TVTX) Q4 2024 Annual Earnings
TVTX·Reported February 20, 2025·After market close
Travere Therapeutics, Inc. reported Q4 2024 revenue of $74.8M, beat analyst consensus of $72.4M by $2.4M. Diluted EPS came in at $-0.73, missed the $-0.58 consensus by $0.15.
Revenue
$74.8Mbeat by $2.4M
Consensus: $72.4MDiluted EPS
$-0.73missed by $0.15
Consensus: $-0.58
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Travere Therapeutics, Inc.'s Q4 2024 earnings report.
Travere Therapeutics, Inc. (TVTX) reported Q4 2024 earnings on February 20, 2025 after market close.
Travere Therapeutics, Inc. reported revenue of $74.8M and diluted EPS of $-0.73 for Q4 2024.
Revenue beat the consensus estimate of $72.4M by $2.4M. EPS missed the consensus estimate of $-0.58 by $0.15.
You can read the 10-K periodic report (0001438533-25-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.